NASDAQ:PALI Palisade Bio (PALI) Stock Price, News & Analysis → Are you prepared for a financial lockdown? (From Weiss Ratings) (Ad) Free PALI Stock Alerts $4.63 -0.01 (-0.22%) (As of 12:51 PM ET) Add Compare Share Share Today's Range$4.46▼$4.6350-Day Range$4.07▼$8.4652-Week Range$3.82▼$36.60Volume4,747 shsAverage Volume704,745 shsMarket Capitalization$4.35 millionP/E RatioN/ADividend YieldN/APrice Target$22.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends Get Palisade Bio alerts: Email Address Palisade Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside396.7% Upside$22.50 Price TargetShort InterestHealthy3.29% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.22Based on 2 Articles This WeekInsider TradingAcquiring Shares$9,670 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($10.81) to ($3.54) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.75 out of 5 stars 3.5 Analyst's Opinion Consensus RatingPalisade Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoveragePalisade Bio has only been the subject of 1 research reports in the past 90 days.Read more about Palisade Bio's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.29% of the float of Palisade Bio has been sold short.Short Interest Ratio / Days to CoverPalisade Bio has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Palisade Bio has recently decreased by 14.49%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPalisade Bio does not currently pay a dividend.Dividend GrowthPalisade Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PALI. Previous Next 1.2 News and Social Media Coverage News SentimentPalisade Bio has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Palisade Bio this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for PALI on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Palisade Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $9,670.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.28% of the stock of Palisade Bio is held by insiders.Percentage Held by InstitutionsOnly 11.79% of the stock of Palisade Bio is held by institutions.Read more about Palisade Bio's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Palisade Bio are expected to grow in the coming year, from ($10.81) to ($3.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Palisade Bio is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Palisade Bio is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPalisade Bio has a P/B Ratio of 0.25. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Palisade Bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsAre you prepared for a financial lockdown?A new kind of American dystopia is being built before our eyes, and most people have no idea what's happening. That's why I've recorded this urgent message to give you all the details on how to prepare … Including three steps to take right now.Click here to watch my video before it's too late. About Palisade Bio Stock (NASDAQ:PALI)Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.Read More PALI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PALI Stock News HeadlinesJune 11, 2024 | globenewswire.comPalisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108June 10, 2024 | globenewswire.comPalisade Bio to Present at the Virtual Investor Pitch ConferenceMay 21, 2024 | finance.yahoo.comPalisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse ModelsMay 21, 2024 | globenewswire.comPalisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse ModelsMay 19, 2024 | finance.yahoo.comPalisade Bio, Inc. (PALI)May 17, 2024 | markets.businessinsider.comBuy Rating Affirmed for Palisade Bio’s PALI-2108 Amid Strong Financials and Promising PartnershipMay 14, 2024 | seekingalpha.comPalisade Bio GAAP EPS of -$4.59May 14, 2024 | globenewswire.comPalisade Bio Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 14, 2024 | msn.comPALI Stock Earnings: Palisade Bio Beats EPS for Q1 2024May 7, 2024 | globenewswire.comPalisade Bio Appoints Margery Fischbein to its Board of DirectorsMay 7, 2024 | globenewswire.comPalisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq RulesMay 2, 2024 | globenewswire.comPalisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq RulesMay 1, 2024 | msn.comMarijuana reclassified federally in major win for the legal cannabis industryMay 1, 2024 | msn.comPalisade Bio stock rallies 50% premarket on colitis drug updateMay 1, 2024 | finance.yahoo.comPalisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)May 1, 2024 | globenewswire.comPalisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)April 23, 2024 | msn.comPalisade Bio, Strand Life Sciences team up on colitis drug researchApril 23, 2024 | msn.comWhy Palisade Bio Stock Is Up TodayApril 23, 2024 | finance.yahoo.comPalisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine ApproachApril 23, 2024 | globenewswire.comPalisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine ApproachApril 19, 2024 | benzinga.comLooking Into Palisade Bio's Recent Short InterestApril 17, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (SAGE) and Palisade Bio (PALI)April 17, 2024 | msn.comHow Apple Car Key Works (and Why It Still Hasn’t Caught On)April 16, 2024 | msn.comPalisade Bio stock rallies nearly 100% on colitis drug analysisApril 16, 2024 | marketwatch.comPalisade Bio Shares Surge 80% After Lab Study Results for Ulcerative Colitis TreatmentSee More Headlines Receive PALI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Palisade Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today6/17/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:PALI CUSIPN/A CIK1357459 Webwww.palisadebio.com Phone(858) 704-4900FaxN/AEmployees9Year FoundedN/APrice Target and Rating Average Stock Price Target$22.50 High Stock Price Target$22.50 Low Stock Price Target$22.50 Potential Upside/Downside+384.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($23.6304) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,300,000.00 Net MarginsN/A Pretax Margin-4,920.00% Return on Equity-105.39% Return on Assets-87.03% Debt Debt-to-Equity RatioN/A Current Ratio4.87 Quick Ratio4.87 Sales & Book Value Annual Sales$250,000.00 Price / Sales17.45 Cash FlowN/A Price / Cash FlowN/A Book Value$18.29 per share Price / Book0.25Miscellaneous Outstanding Shares940,000Free Float905,000Market Cap$4.36 million OptionableNot Optionable Beta1.24 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. J. D. Finley (Age 66)CEO, CFO & Director Comp: $791.33kDr. Mitchell Lawrence Jones M.D. (Age 46)Ph.D., COO & Chief Medical Officer Comp: $635kMr. Ryker WillieSenior VP of Finance & Corporate ControllerKey CompetitorsPlus TherapeuticsNASDAQ:PSTVAptose BiosciencesNASDAQ:APTOOrganovoNASDAQ:ONVOSenti BiosciencesNASDAQ:SNTICoeptis TherapeuticsNASDAQ:COEPView All CompetitorsInsidersDonald Allen WilliamsBought 1,000 shares on 5/28/2024Total: $4,860.00 ($4.86/share)John David FinleyBought 1,000 shares on 5/24/2024Total: $4,810.00 ($4.81/share)Donald Allen WilliamsBought 666 shares on 1/31/2024Total: $5,994.00 ($9.00/share)John David FinleyBought 1,000 shares on 9/27/2023Total: $8,100.00 ($8.10/share)Donald Allen WilliamsBought 1,333 shares on 9/27/2023Total: $10,797.30 ($8.10/share)View All Insider Transactions PALI Stock Analysis - Frequently Asked Questions Should I buy or sell Palisade Bio stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Palisade Bio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PALI shares. View PALI analyst ratings or view top-rated stocks. What is Palisade Bio's stock price target for 2024? 1 analysts have issued twelve-month price targets for Palisade Bio's stock. Their PALI share price targets range from $22.50 to $22.50. On average, they anticipate the company's share price to reach $22.50 in the next year. This suggests a possible upside of 396.7% from the stock's current price. View analysts price targets for PALI or view top-rated stocks among Wall Street analysts. How have PALI shares performed in 2024? Palisade Bio's stock was trading at $8.85 at the beginning of the year. Since then, PALI stock has decreased by 48.8% and is now trading at $4.53. View the best growth stocks for 2024 here. When is Palisade Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024. View our PALI earnings forecast. How were Palisade Bio's earnings last quarter? Palisade Bio, Inc. (NASDAQ:PALI) released its earnings results on Monday, May, 13th. The company reported ($4.59) earnings per share (EPS) for the quarter. When did Palisade Bio's stock split? Shares of Palisade Bio reverse split on Monday, April 8th 2024. The 1-15 reverse split was announced on Monday, April 8th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Palisade Bio? Shares of PALI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PALI) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredThe Scary Fed Idea To Turn Your Dollars Into a Digital Power GrabCash is becoming a relic of the past… Soon, Biden and the Federal Reserve plan to replace the dollar with t...Oasis Gold | Sponsored"Trump Loophole" Beats InflationThe demise of the "petrodollar" appears imminent. And the implications for Americans could be dire.Colonial Metals | SponsoredBiden out June 13; replacement chosen?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palisade Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palisade Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.